August 15, 2022

Healty Care

The Healthy Lovers

Hunter Associates Investment Management LLC Cuts Stake in

5 min read

Hunter Associates Investment Management LLC lessened its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 31,510 shares of the company’s stock after selling 1,250 shares during the quarter. Johnson & Johnson comprises about 1.8% of Hunter Associates Investment Management LLC’s investment portfolio, making the stock its 14th biggest holding. Hunter Associates Investment Management LLC’s holdings in Johnson & Johnson were worth $5,585,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the stock. Magnolia Capital Management Ltd. raised its holdings in shares of Johnson & Johnson by 0.5% in the first quarter. Magnolia Capital Management Ltd. now owns 11,162 shares of the company’s stock valued at $1,978,000 after acquiring an additional 55 shares in the last quarter. Howard Financial Services LTD. boosted its position in Johnson & Johnson by 2.1% in the first quarter. Howard Financial Services LTD. now owns 2,757 shares of the company’s stock valued at $489,000 after buying an additional 57 shares during the last quarter. Capital Investment Counsel Inc boosted its position in Johnson & Johnson by 0.8% in the fourth quarter. Capital Investment Counsel Inc now owns 7,796 shares of the company’s stock valued at $1,334,000 after buying an additional 59 shares during the last quarter. Kwmg LLC boosted its position in Johnson & Johnson by 2.6% in the first quarter. Kwmg LLC now owns 2,354 shares of the company’s stock valued at $417,000 after buying an additional 59 shares during the last quarter. Finally, Beaton Management Co. Inc. boosted its position in Johnson & Johnson by 0.3% in the fourth quarter. Beaton Management Co. Inc. now owns 22,250 shares of the company’s stock valued at $3,806,000 after buying an additional 60 shares during the last quarter. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, insider William Hait sold 29,699 shares of the stock in a transaction on Thursday, April 21st. The stock was sold at an average price of $183.58, for a total value of $5,452,142.42. Following the completion of the transaction, the insider now directly owns 80,236 shares of the company’s stock, valued at approximately $14,729,724.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider William Hait sold 29,699 shares of the firm’s stock in a transaction dated Thursday, April 21st. The shares were sold at an average price of $183.58, for a total value of $5,452,142.42. Following the transaction, the insider now owns 80,236 shares of the company’s stock, valued at $14,729,724.88. The disclosure for this sale can be found here. In the last ninety days, insiders sold 78,161 shares of company stock valued at $13,895,302. 0.35% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Credit Suisse Group upped their target price on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Daiwa Capital Markets assumed coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Citigroup lowered their price objective on Johnson & Johnson from $210.00 to $205.00 in a research report on Tuesday, May 17th. Wells Fargo & Company upped their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, The Goldman Sachs Group upped their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $191.29.

Johnson & Johnson Trading Up 1.5 %

Shares of JNJ stock opened at $178.23 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The company has a market cap of $468.99 billion, a price-to-earnings ratio of 24.02, a PEG ratio of 3.48 and a beta of 0.63. The stock has a 50 day simple moving average of $176.76 and a 200-day simple moving average of $174.35. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, beating the consensus estimate of $2.60 by $0.07. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The firm had revenue of $23.43 billion during the quarter, compared to the consensus estimate of $23.62 billion. During the same period in the prior year, the company earned $2.59 EPS. The firm’s revenue was up 5.0% compared to the same quarter last year. On average, equities research analysts expect that Johnson & Johnson will post 10.21 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were paid a $1.13 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a yield of 2.54%. The ex-dividend date was Monday, May 23rd. Johnson & Johnson’s dividend payout ratio is currently 60.92%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)



Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.